Compugen Ltd. (CGEN)
NASDAQ (CM) NASDAQ (CM) Primary 
TASE 
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event.
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Compugen (CGEN) This Year?
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Compugen: Better Runway Ahead Of MAIA
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway materially improves its risk-reward profile. A positive randomized readout could help validate COM701, and it would be a win for CGEN's broader PVRIG approach.
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen Q2 Earnings Call Highlights
Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Q1 Earnings Call Highlights
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs.
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.08 per share a year ago.
